{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > DasatinibCAS：302962-49-8
Molecular Formula：C22H26ClN7O2S
Molecular Weight：488.01
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 302962-49-8 |
| Name | Dasatinib |
| Molecular Formula | C22H26ClN7O2S |
| Molecular Weight | 488.01 |
| Solubility | Soluble in DMSO |
| Purity | HPLC≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 801-607-0 |
| MDL | MFCD11046566 |
| SMILES | O=C(C1=CN=C(S1)NC2=NC(C)=NC(N3CCN(CC3)CCO)=C2)NC4=C(C=CC=C4Cl)C |
| Target Point | Bcr-Abl;Src;c-Kit |
| Passage | Protein Tyrosine Kinase/RTK |
| Background | Dasatinib is a Bcr-Abl and Src family tyrosine kinase inhibitor. |
| Biological Activity | Dasatinib 是 Bcr-Abl 和 Src 家族酪氨酸激酶抑制剂，抑制Abl， Src，c-Kit和c-KitD816V 的 IC50 分别为0.6，0.8，79和37 nM。[1-6] |
| Data Literature Source | [1]. O'Hare T，et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5. [2]. Shah NP，et al. Dasatinib (BMS-354825) inhibits KITD816V，an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006 Jul 1;108(1):286-91. [3]. Chan CM，et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 1;18(13):3580-91. [4]. Shen Z，et al. Metabolite profiling of dasatinib dosed to Wistar Han rats using automated dried blood spot collection. J Pharm Biomed Anal. 2012 Aug-Sep;67-68:92-7. [5]. Weisberg E，et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors，dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct;26(10):2233-44. [6]. Kan He，et al. Protein kinase inhibitors. Patent. US20180099960A1. |
| Unit | Bottle |
| Specification | 50mg 100mg 500mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
